Progress of Biologics and Small Molecule Drugs in the Treatment of Hidradenitis Suppurativa
- 23 July 2025
- journal article
- review article
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (9) , 1337-1350
Abstract
Hidradenitis suppurativa (HS) is a chronic, debilitating, inflammatory skin disease that is challenging to treat. In recent years, biologic therapies and small‐molecule drugs have been used to improve the treatment landscape of moderate‐to‐severe HS. Biologics, including anti‐tumor necrosis factor‐α agents and interleukin inhibitors, target specific cytokines or cell‐surface receptors involved in the immunopathogenesis of HS. These therapies have shown efficacy in reducing inflammation, pain, and the formation of abscesses and fistulas, as well as in improving patients' quality of life. Small‐molecule drugs offer advantages such as oral administration, potentially different mechanisms of action, targeting of intracellular signaling pathways, and modulation of the immune response. Recent studies have focused on optimizing the use of these drugs, understanding their long‐term effects, and exploring combination therapies. This review summarizes progress in the application of biologics and small‐molecule drugs for the treatment of HS.Keywords
Funding Information
- National Natural Science Foundation of China (82473511)
This publication has 89 references indexed in Scilit:
- The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping reviewArchives of Dermatological Research, 2024
- Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis SuppurativaJAMA Dermatology, 2024
- Spesolimab: First ApprovalDrugs, 2022
- Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis SuppurativaJAMA Dermatology, 2021
- Certolizumab Pegol: A Review in Moderate to Severe Plaque PsoriasisBioDrugs, 2020
- Pregnancy Outcomes After Exposure to Certolizumab PegolArthritis & Rheumatology, 2018
- Canakinumab for Severe Hidradenitis SuppurativaJAMA Dermatology, 2017
- Safety and Efficacy of Anakinra in Severe Hidradenitis SuppurativaJAMA Dermatology, 2016
- Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab PegolBioDrugs, 2014
- Treatment of Hidradenitis Suppurativa With Etanercept InjectionArchives of Dermatology, 2010